-
- TANAHASHI Norio
- Department of Neurology, School of Medicine, Keio University
-
- FUKUUCHI Yasuo
- Department of Neurology, School of Medicine, Keio University
この論文をさがす
抄録
Intravenous thrombolysis with tissue plasminogen activator is currently the most effective treatment of acute ischemic stroke if administerd within 3 hours after symptom onset. Intraarterial thrombolysis by prourokinase is the another choise if the middle cerebral artery is occluded and within less than 6 hours after onset. Although heparin especially a moderate dose is not proved to be effective, a randomized, placebo-controlled trial to determine the safety and efficacy of argatroban (a selective thrombin inhibitor) in patients with acute ischemic stroke was started in USA. Aspirin provides some benefit to patients with acute stroke. However, its effect is not fully satisfactory. Although reports of numerous trials for neuroprotective drugs have been disappointing, edaravone (free radical scavenger) was approved for the treatment of acute ischemic stroke in Japan. In the future, thrombolytic and neuroprotective drugs will be used in combination.<br>(Internal Medicine 41: 337-344, 2002)
収録刊行物
-
- Internal Medicine
-
Internal Medicine 41 (5), 337-344, 2002
一般社団法人 日本内科学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001204867999744
-
- NII論文ID
- 10008450608
-
- NII書誌ID
- AA10827774
-
- COI
- 1:STN:280:DC%2BD38zhs1Gktw%3D%3D
-
- ISSN
- 13497235
- 09182918
-
- NDL書誌ID
- 6169267
-
- PubMed
- 12058880
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可